Talk:Cereblon E3 ligase modulator

Merger proposal

I propose that the articles Immunomodulatory imide drug and Development of analogs of thalidomide should be merged. Both articles cover the exact same topic: immunomodulatory imide drugs and thalidomide analogs are two words for the same thing. While the second article is titled "Development of...", it is much more comprehensive and also includes information on pharmacokinetics, mechanism of action etc., which is lacking in the first article. I think that the articles should be merged under the title Immunomodulatory imide drugs (not "...drug") since this is the name of this drug class. --Shinryuu (talk) 07:58, 10 December 2018 (UTC)

Support merge, and am happy that Immunomodulatory imide drug could be the target. I'd stick with the singular, though, given WP:SINGULAR. There's no special case here; other drug classes use the singular, like: Thiazide, Thiazide-like diuretic, Beta blocker, Sulfonylurea ... Klbrain (talk) 06:36, 12 January 2020 (UTC)

  Y Merger complete. Klbrain (talk) 11:25, 29 February 2020 (UTC)

Requested move 4 December 2023

The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.

The result of the move request was: moved. (closed by non-admin page mover) -- Maddy from Celeste (WAVEDASH) 12:27, 11 December 2023 (UTC)

---

Immunomodulatory imide drug → Cereblon E3 ligase modulator – The current title is not the common name. Since the main mechanism of action of these drugs was definitively discovered, the nomenclature seems to have changed. (t · c) buidhe 05:34, 4 December 2023 (UTC)

See Google Scholar results since 2022,

• "Cereblon E3 ligase modulator" 252
• "Cereblon modulator" 233
• "thalidomide analog" 137
• "Immunomodulatory imide drug" 131

(t · c) buidhe 05:34, 4 December 2023 (UTC)

The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.